CHN MIDTERMS

Question 1

TUBERCULOSIS OR TB is an infectious disease caused by the bacteria called

Answer 1

Mycobacterium tuberculosis, Tubercle bacilli.

Question 2

HOW IS TB TRANSMITTED

Answer 2

through coughing, sneezing and spitting.

Question 3

WHAT ORGANS ARE AFFECTED BY TB

Answer 3

Lungs are commonly affected but it could also affect
other organs such as the kidney, bones, liver, and
others.

Question 4

T/F - TB is not curable

Answer 4

It is curable and preventable. However,
incomplete or irregular treatment may lead to drug-resistant
TB or even death.

Question 5

In 2010, TB was the__ leading cause of
mortality with a rate of __deaths for every ___
population and accounts for __% of total deaths.

Answer 5

6th
26.3
100,000
5.1%

Question 6

TB IS MORE PREVALENT AMONG ___ IN THE 25-55 AGE GROUP

Answer 6

MALES

Question 7

WHO ARE AT RISK OF TB

Answer 7

Malnourished and Diabetics

Question 8

WHEN WAS THE FIRST NATIONAL DRUG RESISTANCE SURVEY DONE

Answer 8

2003-2004

Question 9

Tuberculosis is:

Answer 9

-NOT hereditary
-DOES NOT get caught in fatigue, wakefulness, or
dryness of sweat in the back.
-It is NOT passed on to the use of cutlery or glasses
by a person with TB.
-DO NOT get bitten by mosquitoes.
-It is NOT transmitted through the use of clothing or
blankets by a person with TB.

Question 10

Period of communicability

Answer 10

as long as viable tubercle bacilli are being discharged in
the sputum. Some untreated or inadequately treated
patients may be sputum-positive intermittently for years.

Question 11

Susceptibility and Resistance

Answer 11

the most hazardous period for development of critical
disease is the first 6-12 months after infection. The risk of
developing the disease is highest in children under 3 years
old, lower in later childhood and high again among
adolescents, young adults and the very old.

Question 12

The NTP Control Program was organized in

Answer 12

1978

Question 13

NTP CONTROL PROGRAM IS MANAGED AND ORGANIZED BY

Answer 13

the Infectious Diseases for Prevention and Control Division
(IDPCD) of the Disease Prevention and Control Bureau
(DPCB) of the Department of Health (DOH).

Question 14

NATIONAL TB CONTROL PROGRAM MANDATES:

Answer 14

(1) develop policies, standards and national strategic plan
(2) manage program logistics
(3)provide leadership and technical assistance to the lower
health offices/units
(4) manage data, and
(5) conduct monitoring, and evaluation

Question 15

TB VISION

Answer 15

A Tuberculosis-free Philippines (Zero deaths, disease, and

suffering due to tuberculosis)

Question 16

TB LONG-TERM GOALS

Answer 16

BY 2035 - Reduce TB burden by decreasing TB mortality by 95% and TB incidence by 90%

Question 17

TB MEDIUM-TERM GOALS

Answer 17

Reduce TB burden by:
- decreasing the number of TB deaths by 50% from
22,000 to 11,000
-decreasing TB incidence rate by 15% from
554/100,000 to 470/100,000
-reduce catastrophic costs incurred by TB-affected
households from 35% to 0%
- at least 90% of patients are satisfied with the
services of the DOTS facilities

Question 18

WHAT IS THE PRIMARY DIAGNOSTIC TOOL IN NTP CASE FINDINGS

Answer 18

Direct Sputum Smear Microscopy (DSSM)

Question 19

WHAT IS THE ONLY CONTRAINDICATION FOR SPUTUM COLLECTION

Answer 19

hemoptysis.
in which case, DSSM will be requested after control of
hemoptysis.

Question 20

How is TB treated?

Answer 20

TB-DOTS is the most effective way to treat TB. It only takes
at least 6 months of continuous treatment. Take TB
medicines daily under the guidance of a health service
provider. It is important not to stop the treatment so that TB
(DR-TB) does not reach drug resistance, as the treatment will take longer (up to 24 months) or cause your death.

Question 21

TB - CATEGORY 1

Answer 21

TYPE OF TB PATIENT - New smearpositive PTB New smearnegative PTB with extensive parenchymal lesions on CXR as assessed by the TBDC EPTB, and Severe

TREATMENT REGIMEN INTENSIVE PHASE - 2 months of HRZE Isoniazid (H) Rifampicin (R) Pyrazinamide (Z) Ethambutol (E)

MAINTAINANCE PHASE - 4 months of HR Isoniazid (H) Rifampicin(R)

Question 22

CATEGORY 2

Answer 22

TYPE OF TB PATIENT - New smearpositive PTB New smearnegative PTB with extensive parenchymal lesions on CXR as assessed by the TBDC EPTB, and Severe

TREATMENT REGIMEN INTENSIVE PHASE - 2 months of HRZE Isoniazid (H) Rifampicin (R) Pyrazinamide (Z) Ethambutol (E)

MAINTAINANCE PHASE - 4 months of HR Isoniazid (H) Rifampicin(R)